# Design drug pairs where resisting one makes you vulnerable to the other

Source: https://onco.cc/ideas/idea-bio1-evolutionary-double-bind/  
OnCo record `idea-bio1-evolutionary-double-bind` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Choose two treatments so that whatever the tumour does to escape the first, it becomes easier to kill with the second. The immune system is a good candidate partner.

## Summary

An evolutionary double bind pairs therapies with opposing selection pressures. Examples with preclinical support include MAPK inhibition increasing antigen presentation (making escape via MAPK reactivation immune-visible) and antiandrogen resistance via lineage plasticity creating dependence on EZH2. The proposal is to make double-bind logic an explicit design criterion, with a mechanistic screen for pairs in which resistance to A upregulates the target of B.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Combinations selected for double-bind structure delay resistance in vivo more than combinations selected for additive cytotoxicity, at matched toxicity.
- Rationale: Resistance is a phenotype shift; if the shift can be predicted, the second agent can be aimed at the shifted state. This reframes combination discovery from additive killing to evolutionary trap design.
- Proposed test: Screen resistant derivative panels for upregulated targetable dependencies, validate the top three pairs in immunocompetent models, and take one pair into a phase 1b with mandatory paired biopsies.
- Maturity: preclinical-evidence
- Actor: research

## Sources

- Bottleneck evidence (Tumour heterogeneity and clonal evolution): Gerlinger et al., Intratumor heterogeneity and branched evolution (NEJM 2012): https://doi.org/10.1056/NEJMoa1113205

## Connected records

- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [BRAF](https://onco.cc/targets/braf/), [EZH2](https://onco.cc/targets/ezh2/)
- pathways: [Androgen receptor signalling](https://onco.cc/pathways/ar-signaling/), [RAS / RAF / MEK / ERK (MAPK)](https://onco.cc/pathways/ras-mapk/)
- bottlenecks: [Acquired resistance to every therapy](https://onco.cc/bottlenecks/b-resistance/), [Too many combinations to test](https://onco.cc/bottlenecks/b-combination-space/), [Tumour heterogeneity and clonal evolution](https://onco.cc/bottlenecks/b-tumor-heterogeneity/)

---
JSON: https://onco.cc/api/v1/entities/idea-bio1-evolutionary-double-bind.json